Pregabalin Capsule
Product Images NDC 43598-293

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 29 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 43598-293). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddys Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Figure1)

FDA Label Image

Figure2 (Figure2)

FDA Label Image

Figure3 (Figure3)

FDA Label Image

Figure4 (Figure4)

FDA Label Image

Figure5 (Figure5)

Figure5 (Figure5)
This text describes data related to the percent improvement in pain experienced by patients who were treated with Pregatalin 100 mg, Pregabalin 8 mg, and placeta. However, the information is incomplete and contains errors, making it difficult to provide a more detailed description. *
FDA Label Image

Figure6 (Figure6)

FDA Label Image

Figure7 (Figure7)

FDA Label Image

Carton1 (Carton1)

Carton1 (Carton1)
The text describes a Unit Dose package of Pregabalin Capsules with 25mg strength. The package is not child-resistant and caution is advised to keep it away from children. The package contains 50 capsules in 5 x 10 unit-dose. The drug is intended for institutional use only and the NDC number is provided for the same. The rest of the text contains illegible characters and hence cannot be deciphered.*
FDA Label Image

Carton2 (Carton2)

Carton2 (Carton2)
Pregabalin Capsules in 50 mg strength are packaged in a Unit Dose package that is not child-resistant and intended for institutional use only. The package contains 5 strips of 10 capsules each. The drug should be kept out of reach of children. The National Drug Code (NDC) is 43598-292-66. There is additional unreadable text.*
FDA Label Image

Carton3 (Carton3)

Carton3 (Carton3)
This is a package of Pregabalin Capsules, 75mg strength, intended for institutional use only. The package contains 50 capsules (in 5x10 unit-dose form) manufactured by Dr. Reddys. The package is not child-resistant; hence it warns to keep it out of the reach of children. There is a unique product code NDC 43598-293-66 included for identification purposes. Apart from this, there seem to be some illegible characters and misplaced characters in the text, leading to random words and phrases.*
FDA Label Image

Carton4 (Carton4)

Carton4 (Carton4)
This is a description of a medication called Pregabalin Capsules with a strength of 100mg. It is provided in a unit-dose package containing 50 capsules with each package showing the NDC code as 43598-294-66. The package is not child-resistant. The medication is only available with a prescription and should be kept out of the reach of children in a temperate storage condition. The origin of the medication is Dr. Reddy's Laboratories and the medication contains no more than 6 capsules of 100mg strength.*
FDA Label Image

Carton5 (Carton5)

Carton5 (Carton5)
Pregabalin Capsules (150 mg) are intended for institutional use only and are packaged in unit-dose blister packs of 5 x 10 capsules (50 capsules total). The package is not child-resistant, so it is important to keep it and all drugs out of reach from children. The recommended dosage is one capsule per dose, and they should be stored at a controlled temperature between 20-25°C (68-77°F). The manufacturer is Dr. Reddy's and the product is Rx only. The rest of the text is not discernable and appears to be errors.*
FDA Label Image

Carton6 (Carton6)

Carton6 (Carton6)
This is a package insert for Pregabalin Capsules, containing 200mg medication per capsule. It is intended for institutional use only and is not child-resistant. The pack comes with 50 capsules (5 x 10-unit dose) and should be kept out of reach of children. The medication must be stored at controlled room temperature. The NDC number is 43598-296-66. There is no mention of any side effects or prescriptions.*
FDA Label Image

Carton7 (Carton7)

Carton7 (Carton7)
This is a prescription drug package of 50 capsules containing 225mg of Pregabalin USP, for institutional use only which is not child-resistant. It is advised to keep the medication out of reach of children. The NDC number of the package is 43598-297-66 and should be stored at controlled room temperature.*
FDA Label Image

Carton8 (Carton8)

Carton8 (Carton8)
This is a description of Pregabalin Capsules provided in a unit dose package of 50 capsules (5 x 10 unit-dose) for institutional use only. Each capsule contains 300 mg of Pregabalin US. The package is not child-resistant so it should be kept out of reach of children. The recommended storage is at controlled room temperature.*
FDA Label Image

Container1 (Container1)

FDA Label Image

Container2 (Container2)

FDA Label Image

Container3 (Container3)

FDA Label Image

Container4 (Container4)

FDA Label Image

Container5 (Container5)

FDA Label Image

Container6 (Container6)

FDA Label Image

Container7 (Container7)

FDA Label Image

Container8 (Container8)

FDA Label Image

Figure10 (Figure10)

Figure10 (Figure10)
This appears to be a table or graph with percentages of subjects without LTR (likely related to a medical study) for two groups - one that received Pregabain and another that received a placebo. The values start at 100% for the Pregabain group and decrease gradually while the values for the placebo group start at 0% and increase gradually. The chart spans over a period of 180 days.*
FDA Label Image

Figure11 (Figure11)

FDA Label Image

Figure12 (Figure12)

Figure12 (Figure12)
This appears to be a graph or chart displaying the percent of subjects who improved from baseline to week 16. The data points range from 50 to 100 percent. However, since the text is not entirely clear and there is a lack of context, it is difficult to provide a more specific description.*
FDA Label Image

Figure9 (Figure9)

Figure9 (Figure9)
This appears to be a chart or graph that displays the percentage of patients who experienced improvements in pain levels based on their daily dosage of Pregabalin and Progabalin, as well as a placebo. The x-axis shows different levels of improvement percentages while the y-axis shows the doses of Pregabalin and Progabalin. However, without additional context or a clear image, it is difficult to provide a more detailed description.*
FDA Label Image

Structure1 (Structure1)

FDA Label Image

Structure2 (Structure2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.